| |
IQVIA data scientists have created a framework, known as CASTER, to help you identify potential negative drug-drug interactions and account for them during the drug design process. Download the Insight Brief. .png)
|
|
| By Annalee Armstrong “Scientifically incomplete.” “Grossly deficient.” “Lacking scientific rigor.” These are just a few of the ways the FDA has described BrainStorm Cell Therapeutics’ application for the amyotrophic lateral sclerosis treatment NurOwn—a therapy that has already been rejected twice and is now getting its day before an agency advisory committee meeting after being filed over protest. |
|
|
|
By Max Bayer FDA advisers voted down BrainStorm's cell therapy for ALS, saying that there was not enough evidence to demonstrate the treatment's potential efficacy. The committee also raised issues with the lack of data on the company's manufacturing and delivery process. |
By Fraiser Kansteiner While GSK’s Arexvy was first out the gate in this summer’s respiratory syncytial virus (RSV) vaccine race, Pfizer has kept the pressure up with its rival shot Abrysvo. Now, as the RSV season creeps up, Pfizer’s vaccine has received a formal endorsement from the CDC to be used during pregnancy to protect infants. |
By Nick Paul Taylor AstraZeneca and Daiichi Sankyo are coming for Gilead Sciences' breast cancer business. The partners plan to file for approval of datopotamab deruxtecan (Dato-DXd) after linking their antibody-drug conjugate to improved outcomes, although the immature overall survival data leave a key question unanswered. |
|
Tuesday, October 3, 2023 | 11am ET / 8am PT The life science industry has been growing rapidly. As a result, many biopharma companies are choosing to outsource their analytical method development and testing to CDMOs to fully meet their objectives and foster innovation. Join us to take a deep dive into these critical partnerships and learn key actionable insights. Register now. 
|
|
By Zoey Becker In a critical win, the Padcev-Keyturda combo significantly reduced the risk of death in first-line bladder cancer patients who are eligible for platinum-based chemotherapy at an interim analysis of the closely watched EV-302 trial. |
By Andrea Park Hot on the heels of study data showing that its cuffless blood pressure monitor is well on its way to reaching desired accuracy levels, Rockley Photonics is boasting similar progress in the development of another of its biosensor technologies—this one to monitor blood sugar levels for people with diabetes. |
By Angus Liu As if the talc product liability lawsuits weren’t enough headache for Johnson & Johnson, the New Jersey pharma is now facing another lawsuit from patients, this time about a recent data breach. |
By Nick Paul Taylor AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with Caribou, depriving the biotech of the chance to pocket up to $350 million in milestones per program. |
By Ben Adams Kansas City Chiefs tight end Travis Kelce has recently been the subject of rumors regarding his romantic involvement with singer Taylor Swift, but there is no doubt when it comes to his new pharmaceutical partnership. |
By Helen Floersh Researchers have developed a new injectable hydrogel that maintains plasma concentrations of a common HIV drug, lamivudine—also known as 3TC—for six weeks in mice. Eventually, the scientists hope to add other HIV drugs given alongside 3TC to the same hydrogel, so they can all be administered at once. |
By Kevin Dunleavy By divesting 75% of its API business, Glenmark has finally resolved its debt problem, described by an Indian news outlet as a “decade-long troubled affair.” |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," Heather Landi from Fierce Healthcare engages in a conversation with Othman Laraki, co-founder and CEO of Color Health. They delve into strategies for boosting screenings and explore the partnership between Color Health and the American Cancer Society, aimed at making convenient cancer screenings more accessible. |
|
|---|
|
|
|
Friday, October 6, 2023 | 2pm ET / 11am PT Cellular therapy products such as CAR-T show promising clinical efficacy in fighting cancer. However, the risk of fast-onset cytokine release syndrome (CRS) often results in lengthy hospital stays following infusion. In this webinar, we'll discuss recent research at Mount Sinai on the feasibility of dramatically reducing hospital stays with continuous safety monitoring. Register now. 
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper As the field of real-world data and evidence is constantly evolving, it can be hard to keep-up with best practices. Do you know the definitive characteristics of a high-quality dataset? What questions to ask if you decide to outsource your research to consultants? Here’s everything you need to know in one, must-have guide. Sponsored by: MarketScan by Merative |
Whitepaper Read this paper to learn how pharmaceutical and medical device manufacturers can improve their tender and deal management, as well as how to choose a global management platform and the best practices for implementing it. Sponsored by: Cognizant |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Discover five creative and innovative ways to reimagine your legacy biopharma campus and unlock value. Sponsored by: JLL |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how pharma marketers and other players in the industry can ease the way for consumers, ultimately improving health outcomes and boosting adherence in five simple steps. Sponsored by: Healthline Media |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper Learn how to close the knowledge gap for cancer patients by increasing awareness of important aspects of their condition, treatment options and support resources. Sponsored by: Phreesia Life Sciences |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
